View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
July 7, 2020

Novavax receives $1.6bn from US Government for Covid-19 vaccine

Novavax has received $1.6bn under the US Government’s Operation Warp Speed (OWS) programme to support the development and manufacturing of its Covid-19 vaccine candidate.

Named NVX‑CoV2373, the vaccine is made up of a stable, prefusion protein created using the company’s nanoparticle technology and includes its Matrix‑M adjuvant.

The company will use the funding for late-stage clinical development, large-scale manufacturing and to deliver 100 million doses of NVX‑CoV2373 by late 2020.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU